Cenegermin for the treatment of dry eye disease
Copyright 2023 Clarivate..
Dry eye disease (DED) is the most common ocular surface disorder affecting millions of people worldwide. Due to its chronic nature, the management of DED still represents a challenge in the ophthalmic practice. Nerve growth factor (NGF), which is expressed along with its high-affinity TrkA receptor on the ocular surface complex, has been widely studied for the treatment of neurotrophic keratopathy, and a novel recombinant human NGF (rhNGF) has recently received full market authorization in this setting. Since NGF has shown in both in vitro and in vivo studies to promote corneal healing, to enhance conjunctival epithelium differentiation and mucin secretion, and to stimulate tear film production and functionality, it could provide potential benefits also in patients with DED. A recent phase II clinical trial has assessed the role of rhNGF in DED patients, demonstrating significant improvements of DED signs and symptoms after 4 weeks of treatment. Further clinical evidence will be provided by the 2 ongoing phase III clinical trials. This review aims at comprehensively illustrating the rationale of use along with the efficacy and safety profile of topical NGF in patients with DED.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:59 |
|---|---|
| Enthalten in: |
Drugs of today (Barcelona, Spain : 1998) - 59(2023), 3 vom: 05. März, Seite 113-123 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Coco, Giulia [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9061-61-4 |
|---|
| Anmerkungen: |
Date Completed 02.03.2023 Date Revised 02.03.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1358/dot.2023.59.3.3521858 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM353537403 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM353537403 | ||
| 003 | DE-627 | ||
| 005 | 20231226060229.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1358/dot.2023.59.3.3521858 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1178.xml |
| 035 | |a (DE-627)NLM353537403 | ||
| 035 | |a (NLM)36847622 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Coco, Giulia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cenegermin for the treatment of dry eye disease |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.03.2023 | ||
| 500 | |a Date Revised 02.03.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright 2023 Clarivate. | ||
| 520 | |a Dry eye disease (DED) is the most common ocular surface disorder affecting millions of people worldwide. Due to its chronic nature, the management of DED still represents a challenge in the ophthalmic practice. Nerve growth factor (NGF), which is expressed along with its high-affinity TrkA receptor on the ocular surface complex, has been widely studied for the treatment of neurotrophic keratopathy, and a novel recombinant human NGF (rhNGF) has recently received full market authorization in this setting. Since NGF has shown in both in vitro and in vivo studies to promote corneal healing, to enhance conjunctival epithelium differentiation and mucin secretion, and to stimulate tear film production and functionality, it could provide potential benefits also in patients with DED. A recent phase II clinical trial has assessed the role of rhNGF in DED patients, demonstrating significant improvements of DED signs and symptoms after 4 weeks of treatment. Further clinical evidence will be provided by the 2 ongoing phase III clinical trials. This review aims at comprehensively illustrating the rationale of use along with the efficacy and safety profile of topical NGF in patients with DED | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cenegermin | |
| 650 | 4 | |a Dry eye disease | |
| 650 | 4 | |a Nerve growth factor (NGF) | |
| 650 | 4 | |a Ocular medications | |
| 650 | 7 | |a cenegermin |2 NLM | |
| 650 | 7 | |a B6E7K36KT8 |2 NLM | |
| 650 | 7 | |a Nerve Growth Factor |2 NLM | |
| 650 | 7 | |a 9061-61-4 |2 NLM | |
| 650 | 7 | |a Recombinant Proteins |2 NLM | |
| 700 | 1 | |a Piccotti, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Romano, Vito |e verfasserin |4 aut | |
| 700 | 1 | |a Ferro Desideri, Lorenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Vagge, Aldo |e verfasserin |4 aut | |
| 700 | 1 | |a Traverso, Carlo Enrico |e verfasserin |4 aut | |
| 700 | 1 | |a Pellegrini, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Bruscolini, Alice |e verfasserin |4 aut | |
| 700 | 1 | |a Marenco, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Giannaccare, Giuseppe |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drugs of today (Barcelona, Spain : 1998) |d 1998 |g 59(2023), 3 vom: 05. März, Seite 113-123 |w (DE-627)NLM123139600 |x 1699-3993 |7 nnns |
| 773 | 1 | 8 | |g volume:59 |g year:2023 |g number:3 |g day:05 |g month:03 |g pages:113-123 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1358/dot.2023.59.3.3521858 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 59 |j 2023 |e 3 |b 05 |c 03 |h 113-123 | ||